94,849 Shares in Synopsys, Inc. $SNPS Acquired by NZS Capital LLC

NZS Capital LLC acquired a new stake in shares of Synopsys, Inc. (NASDAQ:SNPS) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 94,849 shares of the semiconductor company’s stock, valued at approximately $46,798,000.

Several other large investors also recently added to or reduced their stakes in SNPS. Lionshead Wealth Management LLC raised its holdings in shares of Synopsys by 1.9% during the 2nd quarter. Lionshead Wealth Management LLC now owns 914 shares of the semiconductor company’s stock valued at $469,000 after purchasing an additional 17 shares in the last quarter. YANKCOM Partnership increased its position in Synopsys by 3.3% during the second quarter. YANKCOM Partnership now owns 537 shares of the semiconductor company’s stock worth $275,000 after buying an additional 17 shares during the last quarter. Manchester Capital Management LLC increased its position in Synopsys by 5.3% during the second quarter. Manchester Capital Management LLC now owns 340 shares of the semiconductor company’s stock worth $174,000 after buying an additional 17 shares during the last quarter. Advisors Capital Management LLC raised its holdings in Synopsys by 2.3% during the second quarter. Advisors Capital Management LLC now owns 862 shares of the semiconductor company’s stock valued at $442,000 after buying an additional 19 shares in the last quarter. Finally, Rothschild Investment LLC lifted its position in shares of Synopsys by 15.9% in the second quarter. Rothschild Investment LLC now owns 153 shares of the semiconductor company’s stock worth $78,000 after buying an additional 21 shares during the last quarter. 85.47% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on SNPS shares. Citigroup began coverage on Synopsys in a report on Monday, November 24th. They set a “buy” rating and a $580.00 price objective on the stock. Wells Fargo & Company decreased their target price on Synopsys from $500.00 to $450.00 and set an “equal weight” rating for the company in a research report on Thursday, February 26th. Rosenblatt Securities lowered their price target on Synopsys from $560.00 to $530.00 and set a “buy” rating on the stock in a report on Thursday, February 26th. Bank of America upgraded shares of Synopsys from an “underperform” rating to a “neutral” rating and reduced their price objective for the stock from $525.00 to $500.00 in a research note on Monday, December 8th. Finally, Needham & Company LLC reiterated a “buy” rating on shares of Synopsys in a research note on Thursday, February 26th. Eight investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Synopsys currently has an average rating of “Hold” and an average price target of $531.00.

Insider Buying and Selling

In related news, insider Janet Lee sold 250 shares of the firm’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $530.00, for a total value of $132,500.00. Following the completion of the transaction, the insider directly owned 11,959 shares of the company’s stock, valued at $6,338,270. This trade represents a 2.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Shelagh Glaser sold 3,657 shares of Synopsys stock in a transaction on Friday, December 19th. The stock was sold at an average price of $460.77, for a total transaction of $1,685,035.89. Following the sale, the chief financial officer owned 17,842 shares in the company, valued at $8,221,058.34. This represents a 17.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 4,157 shares of company stock valued at $1,945,036 in the last quarter. Corporate insiders own 0.56% of the company’s stock.

Synopsys Stock Performance

NASDAQ SNPS opened at $424.32 on Wednesday. The company’s fifty day moving average is $469.06 and its two-hundred day moving average is $472.50. Synopsys, Inc. has a 52-week low of $365.74 and a 52-week high of $651.73. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.36 and a quick ratio of 1.26. The firm has a market capitalization of $81.28 billion, a price-to-earnings ratio of 65.89, a P/E/G ratio of 3.45 and a beta of 1.15.

Synopsys (NASDAQ:SNPS) last released its earnings results on Wednesday, February 25th. The semiconductor company reported $3.77 earnings per share for the quarter, beating the consensus estimate of $3.56 by $0.21. Synopsys had a net margin of 13.76% and a return on equity of 6.83%. The business had revenue of $2.41 billion during the quarter, compared to analysts’ expectations of $2.39 billion. During the same quarter last year, the company earned $3.03 earnings per share. The firm’s revenue was up 65.6% on a year-over-year basis. Synopsys has set its FY 2026 guidance at 14.380-14.460 EPS and its Q2 2026 guidance at 3.110-3.170 EPS. Equities research analysts forecast that Synopsys, Inc. will post 10.64 EPS for the current year.

Synopsys Company Profile

Synopsys, Inc is a leading provider of electronic design automation (EDA) software and semiconductor intellectual property (IP) used to design, verify and manufacture integrated circuits and complex systems-on-chip (SoCs). Its product portfolio spans tools and technologies for front‑end design and synthesis, simulation and verification, physical implementation and signoff, and design-for-manufacturability, enabling chip designers to move from architecture through tape‑out.

In addition to core EDA offerings, Synopsys supplies a broad set of semiconductor IP building blocks — such as interface, memory and analog/mixed-signal cores — that customers integrate into SoCs to accelerate development.